Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report) CFO Alan Fuhrman acquired 9,500 shares of the company’s stock in a transaction on Wednesday, October 30th. The shares were bought at an average price of $16.00 per share, with a total value of $152,000.00. Following the completion of the purchase, the chief financial officer now directly owns 12,849 shares of the company’s stock, valued at approximately $205,584. This represents a 200.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Tyra Biosciences Stock Performance
Shares of TYRA opened at $16.39 on Friday. The business’s fifty day moving average price is $22.39 and its two-hundred day moving average price is $19.88. The firm has a market capitalization of $865.56 million, a price-to-earnings ratio of -9.70 and a beta of 1.08. Tyra Biosciences, Inc. has a 52 week low of $10.60 and a 52 week high of $29.60.
Tyra Biosciences (NASDAQ:TYRA – Get Free Report) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.09. As a group, research analysts forecast that Tyra Biosciences, Inc. will post -1.53 EPS for the current year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
TYRA has been the subject of a number of recent analyst reports. Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and increased their target price for the stock from $22.00 to $31.00 in a research report on Friday, October 18th. Wedbush reiterated an “outperform” rating and issued a $28.00 target price on shares of Tyra Biosciences in a research note on Friday, October 25th. Oppenheimer boosted their target price on Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, September 19th. HC Wainwright raised their price target on Tyra Biosciences from $30.00 to $32.00 and gave the company a “buy” rating in a report on Monday, October 28th. Finally, Piper Sandler started coverage on Tyra Biosciences in a research note on Thursday, August 15th. They issued an “overweight” rating and a $33.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $31.40.
Get Our Latest Stock Analysis on Tyra Biosciences
About Tyra Biosciences
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Featured Stories
- Five stocks we like better than Tyra Biosciences
- There Are Different Types of Stock To Invest In
- Battle of the Retailers: Who Comes Out on Top?
- What is a support level?
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- What is a Stock Market Index and How Do You Use Them?
- MarketBeat Week in Review – 10/28 – 11/1
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.